Lymphoma and Myeloma Cell Resistance to Cytotoxic Agents and Ionizing Radiations Is Not Affected by Exposure to Anti-IL-6 Antibody

PLoS ONE

Volumn 4, Issue 11, 2009, Pages

  Gougelet, Angélique ^a,b   Mansuy, Adeline ^a,b   Blay, Jean Yves ^a,b,c   Alberti, Laurent ^a,b   Vermot Desroches, Claudine ^d  

^a CENTRE LÉON BÉRARD   (France)

^b IID Biotech ^*  (France)

^c EORTC DATA CENTER   (Belgium)

^d IDD Tech   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CELL ADHESION MOLECULE F11; DOXORUBICIN; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 6 RECEPTOR ALPHA; INTERLEUKIN-6 RECEPTOR ALPHA; NERVE CELL ADHESION MOLECULE; SOCS3 PROTEIN, HUMAN; SUPPRESSOR OF CYTOKINE SIGNALING; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CHEMISTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOLOGY; IONIZING RADIATION; LYMPHOMA; METABOLISM; MULTIPLE MYELOMA; TIME; TUMOR CELL LINE;

CELL LINE, TUMOR; DOXORUBICIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INTERLEUKIN-10; INTERLEUKIN-6; LYMPHOMA; MULTIPLE MYELOMA; NEURAL CELL ADHESION MOLECULES; RADIATION, IONIZING; RECEPTORS, INTERLEUKIN-6; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77951224783     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0008026     Document Type: Article

References (47)

1. Trikha M, Corringham R, Klein B, Rossi JF, (2003) Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 9: 4653-4665.
2. Naka T, Nishimoto N, Kishimoto T, (2002) The paradigm of IL-6: from basic science to medicine. Arthritis Res 4 (Suppl 3): S233-S242.
3. Alberti L, Thomachot MC, Bachelot T, Menetrier-Caux C, Puisieux I, et al.(2004) IL-6 as an intracrine growth factor for renal carcinoma cell lines. Int J Cancer 111: 653-661.
4. Klein B, Zhang XG, Jourdan M, Content J, Houssiau F, et al.(1989) Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 73: 517-526.
5. Preti HA, Cabanillas F, Talpaz M, Tucker SL, Seymour JF, et al.(1997) Prognostic value of serum interleukin-6 in diffuse large-cell lymphoma. Ann Intern Med 127: 186-194.
6. Klein B, Zhang XG, Jourdan M, Boiron JM, Portier M, et al.(1990) Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma. Eur Cytokine Netw 1: 193-201.
7. Bachelot T, Ray-Coquard I, Menetrier-Caux C, Rastkha M, Duc A, et al.(2003) Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J Cancer 88: 1721-1726.
8. Negrier S, Perol D, Menetrier-Caux C, Escudier B, Pallardy M, et al.(2004) Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6-from the Groupe Francais d'Immunotherapie. J Clin Oncol 22: 2371-2378.
9. Kishimoto T, (1989) The biology of interleukin-6. Blood 74: 1-10.
10. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L, (1998) Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 334 (Pt 2): 297-314.
11. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, et al.(2003) Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374: 1-20.
12. Krebs DL, Hilton DJ, (2001) SOCS proteins: negative regulators of cytokine signaling. Stem Cells 19: 378-387.
13. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN, (2007) Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608: 1-22.
14. Alas S, Emmanouilides C, Bonavida B, (2001) Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin Cancer Res 7: 709-723.
15. Conze D, Weiss L, Regen PS, Bhushan A, Weaver D, et al.(2001) Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res 61: 8851-8858.
16. Mizutani Y, Bonavida B, Koishihara Y, Akamatsu K, Ohsugi Y, et al.(1995) Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Cancer Res 55: 590-596.
17. Voorzanger-Rousselot N, Favrot M, Blay JY, (1998) Resistance to cytotoxic chemotherapy induced by CD40 ligand in lymphoma cells. Blood 92: 3381-3387.
18. Lotem J, Sachs L, (1996) Differential suppression by protease inhibitors and cytokines of apoptosis induced by wild-type p53 and cytotoxic agents. Proc Natl Acad Sci U S A 93: 12507-12512.
19. Dedoussis GV, Mouzaki A, Theodoropoulou M, Menounos P, Kyrtsonis MC, et al.(1999) Endogenous interleukin 6 conveys resistance to cis-diamminedichloroplatinum-mediated apoptosis of the K562 human leukemic cell line. Exp Cell Res 249: 269-278.
20. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, et al.(1991) Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352: 345-347.
21. Otero DC, Poli V, David M, Rickert RC, (2006) Cutting edge: inherent and acquired resistance to radiation-induced apoptosis in B cells: a pivotal role for STAT3. J Immunol 177: 6593-6597.
22. Tamatani T, Azuma M, Ashida Y, Motegi K, Takashima R, et al.(2004) Enhanced radiosensitization and chemosensitization in NF-kappaB-suppressed human oral cancer cells via the inhibition of gamma-irradiation- and 5-FU-induced production of IL-6 and IL-8. Int J Cancer 108: 912-921.
23. Akmansu M, Unsal D, Bora H, Elbeg S, (2005) Influence of locoregional radiation treatment on tumor necrosis factor-alpha and interleukin-6 in the serum of patients with head and neck cancer. Cytokine 31: 41-45.
24. Petrini B, Andersson B, Strannegard O, Wasserman J, Blomgren H, et al.(1992) Monocyte release and plasma levels of interleukin-6 in patients irradiated for cancer. In Vivo 6: 531-534.
25. Guillemard V, Saragovi HU, (2004) Novel approaches for targeted cancer therapy. Curr Cancer Drug Targets 4: 313-326.
26. Moreau P, Harousseau JL, Wijdenes J, Morineau N, Milpied N, et al.(2000) A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma. Br J Haematol 109: 661-664.
27. Shinomiya N, Kuno Y, Yamamoto F, Fukasawa M, Okumura A, et al.(2000) Different mechanisms between premitotic apoptosis and postmitotic apoptosis in X-irradiated U937 cells. Int J Radiat Oncol Biol Phys 47: 767-777.
28. Zhou ZH, Shi Q, Wang JF, Chen YJ, Zhuang YM, et al.(2005) Sensitization of multiple myeloma and B lymphoma lines to dexamethasone and gamma-radiation-induced apoptosis by CD40 activation. Apoptosis 10: 123-134.
29. Cummings BS, Kinsey GR, Bolchoz LJ, Schnellmann RG, (2004) Identification of caspase-independent apoptosis in epithelial and cancer cells. J Pharmacol Exp Ther 310: 126-134.
30. Razandi M, Pedram A, Levin ER, (2000) Plasma membrane estrogen receptors signal to antiapoptosis in breast cancer. Mol Endocrinol 14: 1434-1447.
31. Turner B, Rapp U, App H, Greene M, Dobashi K, et al.(1991) Interleukin 2 induces tyrosine phosphorylation and activation of p72-74 Raf-1 kinase in a T-cell line. Proc Natl Acad Sci U S A 88: 1227-1231.
32. Johnston JA, Bacon CM, Finbloom DS, Rees RC, Kaplan D, et al.(1995) Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15. Proc Natl Acad Sci U S A 92: 8705-8709.
33. Sommer U, Schmid C, Sobota RM, Lehmann U, Stevenson NJ, et al.(2005) Mechanisms of SOCS3 phosphorylation upon interleukin-6 stimulation. Contributions of Src- and receptor-tyrosine kinases. J Biol Chem 280: 31478-31488.
34. Alas S, Bonavida B, (2001) Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 61: 5137-5144.
35. Mizutani Y, Bonavida B, Nio Y, Yoshida O, (1994) Overcoming TNF-alpha and drug resistance of human renal cell carcinoma cells by treatment with pentoxifylline in combination with TNF-alpha or drugs: the role of TNF-alpha mRNA downregulation in tumor cell sensitization. J Urol 151: 1697-1702.
36. Jourdan M, Tarte K, Legouffe E, Brochier J, Rossi JF, et al.(1999) Tumor necrosis factor is a survival and proliferation factor for human myeloma cells. Eur Cytokine Netw 10: 65-70.
37. Voorzanger N, Touitou R, Garcia E, Delecluse HJ, Rousset F, et al.(1996) Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors. Cancer Res 56: 5499-5505.
38. Zhang X, Blenis J, Li HC, Schindler C, Chen-Kiang S, (1995) Requirement of serine phosphorylation for formation of STAT-promoter complexes. Science 267: 1990-1994.
39. Lufei C, Koh TH, Uchida T, Cao X, (2007) Pin1 is required for the Ser727 phosphorylation-dependent Stat3 activity. Oncogene 26: 7656-7664.
40. Schuringa JJ, Schepers H, Vellenga E, Kruijer W, (2001) Ser727-dependent transcriptional activation by association of p300 with STAT3 upon IL-6 stimulation. FEBS Lett 495: 71-76.
41. Chung J, Uchida E, Grammer TC, Blenis J, (1997) STAT3 serine phosphorylation by ERK-dependent and-independent pathways negatively modulates its tyrosine phosphorylation. Mol Cell Biol 17: 6508-6516.
42. Park J, Ahn KS, Bae EK, Kim BS, Kim BK, et al.(2008) Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically induces the inhibitory effect of bortezomib in human U266 cells. Anticancer Drugs 19: 777-782.
43. Barut BA, Zon LI, Cochran MK, Paul SR, Chauhan D, et al.(1992) Role of interleukin 6 in the growth of myeloma-derived cell lines. Leuk Res 16: 951-959.
44. Borsellino N, Belldegrun A, Bonavida B, (1995) Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res 55: 4633-4639.
45. Visco C, Vassilakopoulos TP, Kliche KO, Nadali G, Viviani S, et al.(2004) Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy. Leuk Lymphoma 45: 2085-2092.
46. Cassatella MA, Gasperini S, Bovolenta C, Calzetti F, Vollebregt M, et al.(1999) Interleukin-10 (IL-10) selectively enhances CIS3/SOCS3 mRNA expression in human neutrophils: evidence for an IL-10-induced pathway that is independent of STAT protein activation. Blood 94: 2880-2889.
47. Niemand C, Nimmesgern A, Haan S, Fischer P, Schaper F, et al.(2003) Activation of STAT3 by IL-6 and IL-10 in primary human macrophages is differentially modulated by suppressor of cytokine signaling 3. J Immunol 170: 3263-3272.